Vande Voort JL
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, USA.
ArticleKetamine
Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial.
ArticleKetamine
Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.
ArticleKetamine
Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.
ArticleKetamine
Next-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel.
ArticleKetamine
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis.
ArticleKetamine
Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study.
ArticleKetamine
Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study.
ArticleKetamine
Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.
ArticleKetamine
Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression.
ArticleKetamine
Intravenous (IV) ketamine versus intranasal esketamine for depression- Advantage IV ketamine?
ArticleKetamine
Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
ArticleKetamine
Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression.
ArticleKetamine
Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report.
ArticleKetamine